CD274 and mature T-cell and NK-cell non-Hodgkin lymphoma: However, treatment‐related any‐grade, Grade ≥3, and serious TEAEs, respectively, were less frequent across all cohorts (50.0%, 0%, 0% [cHL anti‐PD‐1/PD‐L1 naïve]; 91.7%, 0%, 8.3% [cHL anti‐PD‐1/PD‐L1 progressors]; 52.9%, 5.9%, 11.8% [DLBCL]; 72.7%, 27.3%, 18.2% [PTCL]).